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Abstract
The aim of this work was to investigate the mechanism of the vasodilatory effect induced by L-
carnitine. Relaxation produced by L-carnitine was studied in rat aortic rings with and without
functional endothelium, pre-contracted with phenylephrine by adding cumulative doses of L-
carnitine (10­ 7 to 10­ 3 M). The relaxation evoked by L-carnitine reached higher values in aortic rings
from spontaneously hypertensive rats than those obtained in arteries from normotensive rats; no
relaxation was produced in de-endothelialized arteries. However, in the presence of NG-nitro-L-
arginine (3¬ 10­ 5 M, a nitric oxide synthase inhibitor), Ro 68070 (10­ 4 M, a thromboxane synthetase
inhibitor–thromboxane A2/prostaglandin H2 receptorantagonist)or ICI 192605(10­
5
M, a thromboxane
A2 receptor antagonist) the relaxant response to L-carnitine was signi cantly inhibited. These results
show that L-carnitine induced endothelium-dependent relaxation in the rat aorta and the mechanism
of this relaxation appeared to be mostly mediated by endothelial production of nitric oxide but also
could involve prevention of the action of cyclooxygenase endothelial products acting on the
thromboxane A2/prostaglandin H2 receptor.
Introduction
l -Carnitine and its derivates have received increasing attention, mainly because of their
bene® cial eŒects on ischaemic tissues (Bartels et al 1995 ; Tatlican et al 1998), and are
being used in a spectrum of diseases including multiple cardiovascular conditions
(Arsenian 1997). Carnitine has useful properties in some cardiovascular pathologies
such as heart failure (Mancini et al 1992 ; Sethi et al 1999), angina pectoris (Bartels et al
1994 ; Mondillo et al 1995) and arrhythmias (Rizzon et al 1989). In the same way, l -
carnitine has been shown to be useful in patients with essential hypertension and
diabetes (Digiesi et al 1989), because it was able to improve the left ventricle function
and to induce lowering of some fractions of serum lipids (Digiesi et al 1994). Therefore,
l -carnitine might prevent some cardiovascular alterations by its in¯ uence on lipid
metabolism (Rauchova! et al 1998). Despite most published data on carnitine and its
derivates being favourable, clinical trials have been relatively scanty and the mechanism
by which the function during ischaemia is improved is not fully known. An unknown
mechanism of action is implicated in improving the walking capacity in patients with
peripheral vascular disease (Brevetti et al 1992) and alternative mechanisms, in-
dependent of the classical metabolic pathways, have been proposed to explain the
bene® cial eŒects of these compounds (Fritz et al 1993).
The objective of this study was to investigate the possible vasoactive eŒects of l -
carnitine in isolated aorta from spontaneously hypertensive rats and to determine the
contribution of the endothelium to mediating these vasodilatory eŒects.
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Materials and Methods
Chemical reagents and drugs
l -carnitine, acetylcholine chloride, indometacin, NG-nitro-
l -arginine (L-NOARG), noradrenaline (norepinephrine)
bitartrate, phenylephrine hydrochloride and trans-2-
phenylcyclopropyl-amine (tranylcypromine) were pur-
chased from Sigma Chemical Co (St Louis, MO). ICI
192,605 was from Tocris (Biogen Cienti® ca S.L. Spain).
Ridogrel (Ro-68070) was generously provided by Janssen
Pharmaceutical (Beerse, Belgium). The drugs were dis-
solved in distilled water, except indometacin and ICI
192,605 which were dissolved in dimethyl sulfoxide
(DMSO); stock solutions were prepared at 10­ 2 m con-
centration. The ® nal concentration of DMSO in the tissue
bath was less than 0.1% , which was shown to have no
eŒect on the basal tonus of the preparation. All concen-
trations of the drugs used are expressed as ® nal concen-
tration in the organ chamber.
Animals
Male spontaneously hypertensive rats (SHR) and normo-
tensive Wistar Kyoto (WKY) rats, 10± 12 weeks old, weigh-
ing 250± 300 g, were housed at 24 ³ 2 ° C with 60 ³ 20%
relative humidity, on a 12-h light± dark cycle. Rats were
given free access to a diet of standard chow and water.
SHR with systolic pressure (SBP) higher than 170 mmHg
were used in the experiments. All experiments were per-
formed according to the guidelines for the ethical treatment
of animals of the European Union. The rats were killed by
cervical dislocation and the aortae were rapidly dissected.
Aortic ring preparation
The descending thoracic aorta was placed in a modi® ed
Krebs± Henseleit solution (PSS) containing (m m ): NaCl
118, KCl 4.75,NaHCO3 25,MgSO41.2, CaCl2 1.8,KH2PO4
1.2 and glucose 11. After excess fat and connective tissue
were removed, the aortae were cut into 2± 3-mm rings.
Aortic rings were mounted under a basal tension of 2 g in
20-mL organ baths containing PSS and attached to an
isometric transducer (HarvardUF-1);thesignalwas record-
ed by a Powerlab data acquisition system (AD-Instru-
ments). The tissue bath was maintained at 37 ° C and
bubbled with a 95% O2 ± 5% CO2 gas mixture. In some
experiments, the endothelium was mechanically removed
by gently rubbing the intimal surface. The absence of
endothelium was con® rmed by the absence of relaxing
eŒects of acetylcholine (10­ 6 m ) in aortic rings previously
contracted by noradrenaline (norepinephrine) (10­ 5 m ).
Each preparation was allowed to equilibrate for at least
90 min before initiation of experimental procedures, and
during this period the incubation medium was changed
every 20 min (Alvarez de Sotomayor et al 2001).
Relaxant effect of L-carnitine
The relaxant eŒect of l -carnitine was assessed by adding
cumulative concentrations of this drug (10­ 7 to 10­ 3 m ) to
aortic rings precontracted by phenylephrine (3 ¬ 10­ 7 m in
WKY rats or 10­ 6 m in SHR). This experiment was carried
out in both intact and endothelium-denuded arteries.
To analyse the in¯ uence of endothelial factors, vessels
were incubated for 30 min with L-NOARG (3 ¬ 10­ 5 m , an
inhibitor of nitric oxide synthesis), indometacin (10­ 5 m , to
inhibit prostaglandin production), tranylcypromine
(10­ 4 m , a PGI2 inhibitor), ICI 192,605 (10­
5 m , a throm-
boxane A2 receptor antagonist) or ridogrel (Ro-68070 ; a
thromboxane synthetase inhibitor± thromboxane A2}pro-
staglandin H2 receptor antagonist) (10­
4 m ) which were
added to the bath 60 min before the response to phen-
ylephrine was tested. DiŒerent aortic rings were used in
each experiment. After incubation, aortae were contracted
with phenylephrine (3¬ 10­ 7 m or 10­ 6 m ) and when the
contractile response was reached, l -carnitine (10­ 7 to
10­ 3 m )was tested by adding cumulative doses every 15 min,
in the presence of these diŒerent inhibitors. All the results
were expressed as a percentage of the maximal contraction
of phenylephrine-induced responses.
Statistical analysis
Results are expressed as percentages from the initial pre-
contraction level and as means ³ s.e.m (n ¯ 6 rats). Eight
preparations were studied from a single aorta. Analysis of
variance and Tukey’ s multiple comparison test were used
for statistical analysis. P ! 0.05 values were considered to
represent a signi® cant diŒerence. All curves were ® tted by
a concentration± response non-linear regression equation.
Results
Relaxation induced by L-carnitine
Addition of l -carnitine (10­ 7 to 10­ 3 m ) to aortic rings
precontracted with phenylephrine (3 ¬ 10­ 7 and 10­ 6 m for
WKY and SHR, respectively) elicited endothelium-depen-
dent relaxation (P ! 0.01) (Figure 1). The maximal re-














Figure 1 EŒect of l -carnitine (10­ 7 m to 10­ 3 m ) in aortic rings from
SHR (n ¯ 6 in each case, mean³ s.e.m.) precontracted by phen-
ylephrine.E, Control intact endothelium;D, denudedarteries;_, in
the presence of L-NOARG 3¬ 10­ 5 m . **P ! 0.01 vs control with
endothelium.
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laxant eŒect of l -carnitine in intact aortic rings was 36.64 ³
8.3% and 61.71 ³ 7.6% for WKY and SHR, respectively.
Effect of nitric oxide synthase inhibition
To test whether nitric oxide is involved in the endothelium-
dependent relaxation to l -carnitine, the eŒect of nitric
oxide synthase inhibitor L-NOARG (3 ¬ 10­ 5 m ) was stud-
ied. In these conditions, L-NOARG completely inhibited
endothelium-dependent relaxation in aortic rings from
normotensive rats. Pre-incubation with L-NOARG also
inhibited l -carnitine-induced relaxation in arteries ob-
tained from SHR (P ! 0.01). However, in the SHR aortic
rings, at l -carnitine concentrations in the range 10­ 6 to
10­ 5 m an L-NOARG-resistant relaxant eŒect remained
(Figure 1).
Involvement of prostanoids in the effect of
L-carnitine
The presence of the cyclooxygenase inhibitor indometacin
(10­ 5 m ) did not aŒect endothelium-dependent relaxation
in eitherWKYor SHR aortic rings. When both nitric oxide
synthase and cyclooxygenase were blocked together, the L-
NOARG-resistant relaxation in SHR aortic rings was
inhibited (Figure 2).
The eŒects of synthetase inhibitor± thromboxane A2}
prostaglandin H2 receptor antagonist Ro 68070 (10­
4 m )
and thromboxane A2}prostaglandin H2 receptor antagon-
ist ICI 192,605 (10­ 5 m ) were also tested. Both Ro 68070
and ICI 192,605 were able to signi® cantly inhibit the
endothelial relaxant response to l -carnitine in SHR arteries
(Figure 3). When testing the combination of L-NOARG
plus Ro 68070, the results obtained were the same as those
observed with L-NOARG plus indometacin.
As shown in Figure 4, the prostacyclin synthetase in-
hibitor, tranylcipromine (10­ 4 m ), did not have any signi® -














Figure 2 EŒect of l -carnitine (10­ 7 m to 10­ 3 m ) in aortic rings from
SHR (n ¯ 6 in each case, mean³ s.e.m.) precontracted by phen-
ylephrine. E, Control intact endothelium; D, in the presence of
indometacin 10­ 5 m ;_, in the presence of indometacin 10­ 5 m plus L-
NOARG 3 ¬ 10­ 5 m . **P ! 0.01 vs control with endothelium.
















Figure 3 EŒect of l -carnitine (10­ 7 m to 10­ 3 m ) in aortic rings from
SHR (n ¯ 6 in each case, mean³ s.e.m.) precontracted by phen-
ylephrine.E, Control intact endothelium; D, in the presence of Ro
68070 10­ 4 m ;_, in the presence of Ro 68070 10­ 4 m plus L-NOARG
3¬ 10­ 5 m ; +, in the presence of ICI 192,605 10­ 5 m . **P ! 0.01 vs
control with endothelium.
cant eŒect on concentration± response curves to l -carnitine.
Pre-incubation with tranylcipromine plus L-NOARG did
not aŒects the results obtained with L-NOARG alone.
Discussion
Carnitine has sometimes been bene® cial as a therapeutic
agent. Examples include cardiac myopathies and peripheral
arterial disease (Ferrari et al 1992), and improving the
walking capacity in patients with peripheral vascular dis-
ease (Brevetti et al 1992). In animal models, l -carnitine and
its derivatives have shown some bene® cial eŒect such as
protection against the development of vascular lesions in
peripheral arterial insu ciency induced by intra-arterial
injection of sodium laurate (Corsico et al 1993), the pre-
vention of progression of atherosclerotic lesions (Spagnoli
et al 1995) and age-dependent rise of plasma total chol-
esterol, triglycerides and uric acid of SHR (Rauchova! et al
1998) and the reduction in polyploid cells also in SHR
(Mauriello et al 1996). However, the mechanism of action
implicated in some of the therapeutic applications of l -
carnitine is still unclear.
The aim of this study was to investigate the vasodilatory
eŒect of l -carnitine on isolated thoracic aorta from sponta-
neously hypertensive rats (SHR) and their normotensive
genetic control Wistar Kyoto (WKY) rats. The results
provide direct evidence of the involvement of endothelium
in the concentration-dependent vasorelaxation induced by
l -carnitine. Most of this endothelium-dependent eŒect
seems to bemediated by nitric oxide because in the presence
of L-NOARG, the inhibitor of nitric oxide synthesis, the
relaxation to l -carnitine was signi® cantly diminished com-
pared with that of intact arteries from both WKY rats
and SHR. The response of arteries in the presence of L-
NOARGwas similar to that of denuded arteries. However,
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Figure 4 EŒect of l -carnitine (10­ 7 m to 10­ 3 m ) in aortic rings from
SHR (n ¯ 6 in each case, mean³ s.e.m.) precontracted by phen-
ylephrine. E, Control intact endothelium; D, in the presence of
tranylcipromine 10­ 4 m ;_, in the presence of tranylcipromine 10­ 4 m
plus L-NOARG 3 ¬ 10­ 5 m . **P ! 0.01 vs control with endothelium.
SHR aortic rings showed an L-NOARG-resistant relaxant
eŒect in response to low concentrations of l -carnitine,
indicating that the production of nitric oxide was involved
in mediating the vasodilatory eŒects of l -carnitine but it
did not seem to be the only endothelial factor released by l -
carnitine addition. In contrast, the cyclooxygenase inhibi-
tor, indometacin, did not aŒect the endothelium-dependent
response to l -carnitine. However, exposure to indometacin
plus L-NOARG resulted in a larger inhibitory eŒect than
L-NOARG alone, abolishing completely the response of
intact arteries to l -carnitine, removing the remaining eŒect.
These data led us to think that the vasodilator properties of
l -carnitine might involve the participation of vasoactive
products from cyclooxygenase, endothelial relaxant or
vasoconstrictor factors in addition to nitric oxide.
To verify the nature of endothelial products from the
cyclooxygenase possibly involved in the vasodilator pro-
perties of l -carnitine, the presence of a prostacyclin syn-
thetase inhibitor did not signi® cantly aŒect the concentra-
tion± response curve. When the same inhibitor was used in
addition to L-NOARG, the result was similar to that
obtained in the presence of indometacin plus L-NOARG,
suggesting that prostaglandin I2 could be involved, but its
eŒect was only obvious when nitric oxide synthesis was
blocked. Incubation with Ro 68070 and ICI 192,605 signi® -
cantly decreased the sensitivity and maximal relaxation to
l -carnitine in arteries from SHR rats. Taken together,
these data suggest that l -carnitine could prevent the vaso-
constrictor action of cyclooxygenase endothelial products
acting on the thromboxane A2}prostaglandin H2 receptor.
This observation could help explain how l -carnitine was
more eŒective in relaxing arteries from hypertensive rats
than from normotensive rats since the release of this
endothelium-dependent contracting factor (EDCF) (in-
cluding endoperoxides and thromboxane A2) explains the
abnormal relaxations (Auch-Schwelk et al 1992) and
contractions to acetylcholine (Auch-Schwelk et al 1990)
observed in the aorta and small resistance arteries of the
SHR. The EDCF released from the hypertensive endo-
thelium interacts chemically with nitric oxide, and both
mediators inactivate each other (Ito et al 1991 ; Auch-
Schwelk et al 1992). Such a chemical interaction explains
the blunting of endothelium-dependent relaxations, despite
a normal ability of the endothelial cells to release endo-
thelium-derived relaxing factors (Vanhoutte 1996). This
larger release of prostaglandin H2 or thromboxane A2 in
the SHR may result from a greater production (Ge et al
1995). On the other hand, oxidative stress can accompany
hypertension in many models, including the SHR (Wilcox
2002). It has been shown that hypertension leads to
enhanced superoxide production in the vasculature (Kojda
et al 1999). Therefore, we cannot discard the possibility
that carnitine might also possess bene® cial eŒects on super-
oxide anion production in addition to nitric oxide bio-
availability.
Conclusion
This study provides evidence of a vascular relaxation in
response to l -carnitine in the aorta of hypertensive rats.
The mechanism appeared mostly to be mediated by en-
dothelial production of nitric oxide but also could involve
prevention of the action of cyclooxygenase endothelial
products acting onTXA2}PGH2 receptors without discard-
ing the possibility that carnitine might also possess bene-
® cial eŒects on superoxide anion production. These ® nd-
ings in relation to endothelial function might help to better
understand the bene® cial cardiovascular eŒects of l -carni-
tine.
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